A Phase 1/2 Open-label Study in Patients With Arginase I Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102

Trial Profile

A Phase 1/2 Open-label Study in Patients With Arginase I Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Sep 2017

At a glance

  • Drugs Pegzilarginase (Primary)
  • Indications Inborn error metabolic disorders
  • Focus Adverse reactions; Proof of concept
  • Sponsors Aeglea Biotherapeutics
  • Most Recent Events

    • 06 Sep 2017 According to an Aeglea BioTherapeutics media release, the company has dosed two adults in the repeat dose part of this trial. Topline data is expected in second half of 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 23 May 2017 According to an Aeglea BioTherapeutics media release, the company has received two Institutional Review Board (IRB) approvals for the protocol of this trial and has an open Clinical Trial Application (CTA) in Canada.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top